Pacira BioSciences (PCRX) Scheduled to Post Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX) is scheduled to announce its earnings results after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). The business had revenue of $167.12 million during the quarter, compared to the consensus estimate of $165.43 million. Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Trading Up 0.3 %

Shares of PCRX opened at $20.03 on Monday. Pacira BioSciences has a 1-year low of $19.34 and a 1-year high of $40.16. The firm has a market capitalization of $932.40 million, a price-to-earnings ratio of 14.01 and a beta of 0.88. The company has a 50-day moving average of $26.02 and a 200 day moving average of $28.21. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.81 and a quick ratio of 4.78.

Insider Activity

In other Pacira BioSciences news, COO Daryl Gaugler sold 1,000 shares of the stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the sale, the chief operating officer now owns 116,040 shares of the company’s stock, valued at approximately $3,293,215.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Daryl Gaugler sold 1,000 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the transaction, the chief operating officer now owns 116,040 shares of the company’s stock, valued at $3,293,215.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Slonin sold 5,012 shares of Pacira BioSciences stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $28.57, for a total value of $143,192.84. Following the sale, the insider now directly owns 44,569 shares of the company’s stock, valued at $1,273,336.33. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,150 shares of company stock worth $602,170. Corporate insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

PCRX has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $43.00 target price on shares of Pacira BioSciences in a research report on Tuesday, July 2nd. Piper Sandler reiterated an “overweight” rating and issued a $42.00 target price on shares of Pacira BioSciences in a research report on Wednesday, July 3rd. Barclays downgraded shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $38.00 to $25.00 in a report on Wednesday, July 3rd. Truist Financial cut their price target on Pacira BioSciences from $45.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Pacira BioSciences in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.60.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.